This preprint quantifies the contribution of polygenic risk to the burden of non-communicable diseases (NCDs) in Taiwan and examines how genetic liability relates to healthcare utilization. The authors analyzed linked data from Taiwan Biobank and the National Health Insurance Research Database in a sample of approximately 140,000 individuals to study 42 high-burden NCDs. Elevated genetic risk (PRS_e) was operationalized as the top 10% of polygenic risk score distribution. Cox proportional hazards models were used to estimate associations between PRS_e and incident disease, and results were converted into population-level and individual-level burden metrics.
The primary data sources were the Taiwan Biobank (TWB) and the National Health Insurance Research Database (NHIRD). The combined dataset included around 140,000 participants. Taiwan-specific disability and burden inputs were taken from the Global Burden of Disease 2023 estimates to calculate DALYs and to contextualize population attributable fractions for each disease. The authors report that data and code are available on request from the study team.
Elevated polygenic risk (PRS_e) was defined as the top decile (top 10%) of the PRS distribution for each trait. Cox proportional hazards models estimated hazard ratios (HRs) for incident disease associated with PRS_e. The study translated relative risks into population attributable fractions (PAFs) to express the proportion of disease incidence in the population attributable to high polygenic risk. Individual-level attributable burden was expressed in terms of healthy life-years lost and DALYs using Taiwan-specific Global Burden of Disease inputs.
PAFs were calculated to quantify the proportion of incident disease at the population level attributable to PRS_e for each of the 42 NCDs analyzed. Disability-adjusted life years (DALYs) attributable to PRS_e were estimated using Taiwan-specific burden estimates from the Global Burden of Disease 2023. The study reports both population-level DALYs and individual-level healthy life-years lost attributable to high polygenic risk.
The strongest PRS_e associations by hazard ratio were observed for atrial fibrillation (AFib) (HR = 3.56; 95% CI: 3.23–3.92) and gout (HR = 2.41; 95% CI: 2.33–2.49). These translated into estimated PAFs of about 20% for AFib and 12% for gout. At the population level, the largest polygenic-attributable DALYs were reported for type 2 diabetes (T2D), intracranial hemorrhage (ICH), and lung cancer. At the individual level, PRS_e corresponded to estimated healthy life-years lost of 1.50 (95% CI: 1.42–1.57) for T2D and 0.57 (95% CI: 0.40–0.76) for ICH. Individuals in the top 1% PRS had estimated losses approaching 2.4 healthy life-years, according to the reported results.
The authors report that the polygenic attributable burden was overall greater in men than in women across the diseases examined. The manuscript provides sex-stratified comparisons for PAFs and DALYs where applicable.
For several diseases, the PAFs and DALYs associated with PRS_e exceeded those attributed to individual modifiable risk factors (MRFs) such as smoking and alcohol use. The article highlights that for select conditions PRS-associated burden is comparable to—or larger than—some single MRFs, underscoring the potential public health relevance of polygenic liability. Specific disease-by-risk-factor comparisons are presented in the study results.
The investigators derived an integrated polygenic risk score (iPRS) and assessed associations with healthcare utilization indicators. Participants in the top decile of iPRS had higher healthcare use: 23.9% more hospital days (95% CI: 15.0–33.6%), 19.1% more inpatient visits (95% CI: 13.2–25.3%), and 9.6% more outpatient visits (95% CI: 6.9–12.4%). These findings link higher genetic liability to measurable increases in healthcare services consumption in this Taiwanese cohort.
The study reports ethical approvals from the Taiwan Biobank Ethics and Governance Council (approval TWBR11211-02) and the Institutional Review Board of National Taiwan University Hospital (202308103RINB). Taiwan Biobank obtained informed consent from participants for research use of collected data. The authors state that all data produced are available upon reasonable request.
The authors interpret their findings to indicate that polygenic risk accounts for a measurable share of NCD burden in Taiwan and, for several diseases, a share comparable to individual modifiable risk factors. They propose that these quantitative estimates provide a foundation for integrating genetic liability into preventive care strategies and health planning. As a preprint, the work has not undergone peer review; the authors themselves note that it reports new research that should not yet guide clinical practice.